埃索美拉唑(耐信)哪里可以买到

(Nexium) is a drug developed by AstraZeneca Pharmaceuticals. It is mainly used for gastroesophageal reflux disease (GERD). It can also be used in combination with appropriate antibacterial therapy to eradicate Helicobacter pylori, and can heal duodenal ulcers related to Helicobacter pylori infection and prevent the recurrence of peptic ulcers related to Helicobacter pylori infection.

Because esomeprazole (Nexium) is already on the market in my country, patients can basically buy it in regular domestic pharmacies or hospitals. Several clinical trials have shown that esomeprazole is more effective than omeprazole. Moreover, oral medications are more convenient to use, bringing a simple and effective treatment plan to patients with gastroesophageal reflux disease (GERD).

In order to ensure the effective effect of drugs, correct use of drugs is essential. The recommended dosage of esomeprazole (Nexium) varies depending on the symptoms. The recommended dose for patients with erosive reflux esophagitis is 40 mg once daily for 4 weeks. For patients whose esophagitis is not cured or whose symptoms persist, a further 4 weeks of treatment is recommended.

For long-term maintenance treatment of cured esophagitis patients to prevent recurrence, the recommended dose of esomeprazole is 20 mg once daily. The recommended dosage for symptom control of GERD is as follows: 20 mg once a day for patients without esophagitis. If symptoms are not controlled after 4 weeks of medication, the patient should undergo further examination. After the symptoms disappear, you only need to take 20 mg orally once a day when needed.

In addition to the domestic (Nexium) original drug, more and more patients are also choosing to buy the Indian version of esomeprazole, which is produced by SUN Pharmaceuticals in India. The price is relatively low. Patients can go to the local regular pharmacy to buy it in person, or they can consult the medical companion travel service to learn about the regular purchase method.

Recommended related hot articles: /newsDetail/79769.html